2022
Technology and Mental Health: State of the Art for Assessment and Treatment
Harvey PD, Depp CA, Rizzo AA, Strauss GP, Spelber D, Carpenter LL, Kalin NH, Krystal JH, McDonald WM, Nemeroff CB, Rodriguez CI, Widge AS, Torous J. Technology and Mental Health: State of the Art for Assessment and Treatment. American Journal Of Psychiatry 2022, 179: 897-914. PMID: 36200275, DOI: 10.1176/appi.ajp.21121254.Peer-Reviewed Original ResearchConceptsHigh-quality evidenceEcological momentary assessmentTechnology-based interventionsMental health applicationsClinical trialsTreatment strategiesCognitive trainingFunctional capacityDrug AdministrationSystematic reviewVirtual reality approachMomentary assessmentU.S. FoodMental healthFunctional skillsTechnology-based assessmentInterventionTechnology-based approachesTreatmentAssessmentHealth applicationsPhysiological parametersReality approachReviewEmotions
2016
Neuropsychological Functioning in Veterans with Posttraumatic Stress Disorder: Associations with Performance Validity, Comorbidities, and Functional Outcomes
Wrocklage KM, Schweinsburg BC, Krystal JH, Trejo M, Roy A, Weisser V, Moore TM, Southwick SM, Scott JC. Neuropsychological Functioning in Veterans with Posttraumatic Stress Disorder: Associations with Performance Validity, Comorbidities, and Functional Outcomes. Journal Of The International Neuropsychological Society 2016, 22: 399-411. PMID: 26892753, DOI: 10.1017/s1355617716000059.Peer-Reviewed Original ResearchConceptsNeuropsychological functioningGroup differencesValidity concernsPhysical health-related qualityDomains of speedPosttraumatic stress disorderInformation processing performanceEpisodic memoryAttention/Executive functionLanguage functioningPerformance validityCognitive functioningDisorder displayNeurocognitive domainsNeurocognitive findingsNeurocognitive functioningComparison participantsPTSD groupNeuropsychological testsStress disorderMost prior researchOccupational functioningNeuropsychological resultsPTSD status
2015
A Quantitative Meta-Analysis of Neurocognitive Functioning in Posttraumatic Stress Disorder
Scott JC, Matt GE, Wrocklage KM, Crnich C, Jordan J, Southwick SM, Krystal JH, Schweinsburg BC. A Quantitative Meta-Analysis of Neurocognitive Functioning in Posttraumatic Stress Disorder. Psychological Bulletin 2015, 141: 105-140. PMID: 25365762, PMCID: PMC4293317, DOI: 10.1037/a0038039.Peer-Reviewed Original ResearchConceptsPosttraumatic stress disorderVerbal memoryInformation processingVerbal learningAttention/Cognitive domainsComparison participantsStress disorderCognitive deficitsAttention-deficit/hyperactivity disorderEffect size estimatesHealthy comparison participantsQuantitative Meta-AnalysisEffect sizeLarge effect sizesVisual memoryCognitive modelExecutive functionVisual learningVisuospatial abilitiesNeuropsychological functioningTrauma exposureNeurocognitive functioningHyperactivity disorderPTSD group
2014
Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
Boggs DL, Carlson J, Cortes-Briones J, Krystal JH, D'Souza DC. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia. Current Pharmaceutical Design 2014, 20: 5077-92. PMID: 24345265, PMCID: PMC4442779, DOI: 10.2174/1381612819666131216121019.Peer-Reviewed Original ResearchConceptsCognitive impairmentStandardized cognitive test batteryCognitive test batteryInformation processing impairmentsNicotinic medicationsProcessing impairmentsCore deficitAttentional deficitsTest batteryCognitive deficitsProximal measuresBrain functionCognitionSchizophreniaDeficitsImpairmentNumber of medicationsNicotinic acetylcholine receptorsCertain symptomsConsistent improvementClinical evidenceTreatment strategiesClinical studiesNicotinic receptorsClinical utility
2013
New drug development for cognitive enhancement in mental health: Challenges and opportunities
Insel T, Krystal J, Ehlers M. New drug development for cognitive enhancement in mental health: Challenges and opportunities. Neuropharmacology 2013, 64: 2-7. PMID: 23145450, DOI: 10.1016/j.neuropharm.2012.07.041.Peer-Reviewed Original Research
2012
Linking Microcircuit Dysfunction to Cognitive Impairment: Effects of Disinhibition Associated with Schizophrenia in a Cortical Working Memory Model
Murray JD, Anticevic A, Gancsos M, Ichinose M, Corlett PR, Krystal JH, Wang XJ. Linking Microcircuit Dysfunction to Cognitive Impairment: Effects of Disinhibition Associated with Schizophrenia in a Cortical Working Memory Model. Cerebral Cortex 2012, 24: 859-872. PMID: 23203979, PMCID: PMC3948492, DOI: 10.1093/cercor/bhs370.Peer-Reviewed Original ResearchConceptsWorking memoryNeural levelSpatial WM taskWorking Memory ModelSpatial working memoryPersistent activity patternsWM representationsWM taskWM maintenanceBrain mechanismsWM deficitsMicrocircuit dysfunctionPrefrontal cortexCognitive deficitsBehavioral dataMemory modelBehavioral variabilityWM deteriorationCognitive impairmentCortical disinhibitionExcitation-inhibition balanceMain model predictionsDisinhibitionBehavioral deficitsDeficitsThe role of default network deactivation in cognition and disease
Anticevic A, Cole MW, Murray JD, Corlett PR, Wang XJ, Krystal JH. The role of default network deactivation in cognition and disease. Trends In Cognitive Sciences 2012, 16: 584-592. PMID: 23142417, PMCID: PMC3501603, DOI: 10.1016/j.tics.2012.10.008.Peer-Reviewed Original ResearchConceptsDMN suppressionDefault network deactivationGoal-directed cognitionSpecific behavioral tasksDefault mode networkCognitive neurosciencePharmacological neuroimagingSuppression deficitsBehavioral tasksFocused attentionClinical neuroscienceTheoretical neuroscienceBrain regionsNeuroscienceCognitionSevere mental illnessMental illnessConsiderable bodyNeuroimagingTaskDeficitsDMNExternal environmentMindDiseaseGlycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptomsMild Worry Symptoms Predict Decline in Learning and Memory in Healthy Older Adults: A 2-Year Prospective Cohort Study
Pietrzak RH, Maruff P, Woodward M, Fredrickson J, Fredrickson A, Krystal JH, Southwick SM, Darby D. Mild Worry Symptoms Predict Decline in Learning and Memory in Healthy Older Adults: A 2-Year Prospective Cohort Study. American Journal Of Geriatric Psychiatry 2012, 20: 266-275. PMID: 22354117, PMCID: PMC3285262, DOI: 10.1097/jgp.0b013e3182107e24.Peer-Reviewed Original ResearchConceptsWorry symptomsOlder adultsCommunity-dwelling older adultsCognitive functionAge-related cognitive changesHealthy Older AdultsImportance of anxietyEarly cognitive declineDepressive symptomsAssociate learningCognitive agingVisual learningCognitive changesProspective cohort studyCognitive declineDepression symptomsEarly dementiaCohort studyObservational prospective cohort studyMemoryMild levelsLearningWorryAdultsTheoretical model
2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders
Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, Cohen JD, Geyer M, Gollub R, Green MF, Jaeger J, Krystal JH, Moore H, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders. Biological Psychiatry 2011, 70: 7-12. PMID: 21529781, PMCID: PMC3116022, DOI: 10.1016/j.biopsych.2011.01.041.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, PharmacologicalBrain MappingCognition DisordersDisease Models, AnimalDrug DiscoveryHumansSchizophreniaConceptsCognitive Neuroscience Treatment ResearchTreatment researchCognitive neuroscienceTreatment developmentFunctional magnetic resonance imagingSchizophrenia (MATRICS) initiativeSchizophrenia IIPotential confoundsImpaired cognitionCognitionNeural systemsNeural activityPsychometric propertiesMental healthBrain functionTranscranial magnetic simulationNeuroscienceTreatment effectsSchizophreniaMulticenter phase IITranslational researchImproved animal modelsPragmatic issuesBiological psychiatryMagnetic resonance imaging
2008
Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting
Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, Green MF, Krystal JH, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting. Schizophrenia Bulletin 2008, 35: 109-114. PMID: 19023126, PMCID: PMC2643950, DOI: 10.1093/schbul/sbn163.Peer-Reviewed Original ResearchMeSH KeywordsClinical Trials as TopicCognition DisordersCognitive ScienceHumansNeurosciencesSchizophreniaConceptsFirst CNTRICS meetingCognitive neuroscienceCognitive Neuroscience Treatment ResearchPromising taskSchizophrenia (MATRICS) initiativeTreatment researchBroad domainsTaskSuch paradigmsNeuroscienceSpecific paradigmSpecific tasksRelevant paradigmConstructsParadigmLine surveyCognitionSpecial issueGoalNominationsDomainResearchInformationArticleTrialsIdentifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry 2008, 64: 4-10. PMID: 18466880, PMCID: PMC2577821, DOI: 10.1016/j.biopsych.2008.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsBiomedical ResearchBrainCognition DisordersCooperative BehaviorDrug IndustryHumansNational Institute of Mental Health (U.S.)Neuropsychological TestsResearch Support as TopicSchizophreniaSchizophrenic PsychologyUnited StatesUnited States Food and Drug AdministrationConceptsCognitive Neuroscience Treatment ResearchSchizophrenia (MATRICS) initiativeTreatment researchCognitive neuroscience fieldCNTRICS initiativeCognitive mechanismsCognitive constructsTreatment developmentNeuroscience fieldCognitive impairmentCognitionBasic animalSchizophreniaResearchFirst meetingImpairmentConstructsParadigmTranslational researchTranslation effortsNovel treatmentsOrganization
2005
Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia
Cho RY, Ford JM, Krystal JH, Laruelle M, Cuthbert B, Carter CS. Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia. Schizophrenia Bulletin 2005, 31: 865-869. PMID: 16166611, DOI: 10.1093/schbul/sbi050.Peer-Reviewed Original ResearchMeSH KeywordsCognition DisordersElectrophysiologyEndpoint DeterminationHumansMagnetic Resonance ImagingReproducibility of ResultsSchizophreniaConceptsFunctional neuroimagingCognitive impairmentCognitive processesNeurobiological indicesTest-retest reliabilityCognitive functionTreatment researchDiscrepant findingsCognitionMental healthAdditional basic researchSchizophreniaNeuroimagingNovel pharmacotherapeuticsImpairmentParadigmResearchParticipantsBasic researchNIMHMatricFindingsRelative advantagesTrialsPerspective
2000
Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists
Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH. Attenuation of the Neuropsychiatric Effects of Ketamine With Lamotrigine: Support for Hyperglutamatergic Effects of N-methyl-D-aspartate Receptor Antagonists. JAMA Psychiatry 2000, 57: 270-276. PMID: 10711913, DOI: 10.1001/archpsyc.57.3.270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAffectBrief Psychiatric Rating ScaleCognition DisordersDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamatesHumansKetamineLamotrigineMaleMental DisordersPerceptual DisordersPlacebosPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSchizophreniaSchizophrenic PsychologyTriazinesVerbal LearningConceptsN-methyl-D-aspartate receptor antagonistNMDA receptor dysfunctionReceptor antagonistNeuropsychiatric effectsGlutamate releaseReceptor dysfunctionSymptom subscalesPlacebo 2 hoursClinician-Administered Dissociative States ScaleAdministration of lamotrigineAdministration of ketamineDouble-blind conditionsNMDA receptor antagonistMood-elevating effectsPositive symptom subscaleBrief Psychiatric RatingNovel therapeutic agentsNegative symptom subscaleHopkins Verbal Learning TestVerbal Learning TestKetamine effectsPsychiatric illnessHealthy subjectsPathophysiologic processesPreclinical studiesDissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions
Krystal J, Bennett A, Abi-Saab D, Belger A, Karper L, D’Souza D, Lipschitz D, Abi-Dargham A, Charney D. Dissociation of ketamine effects on rule acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive cognitive functions. Biological Psychiatry 2000, 47: 137-143. PMID: 10664830, PMCID: PMC10060085, DOI: 10.1016/s0006-3223(99)00097-9.Peer-Reviewed Original ResearchConceptsExecutive cognitive functionSecond test dayPerseverative errorsWCST performanceCognitive functionTest daySecond studyExecutive componentTask repetitionAltered perceptionWCSTNMDA antagonist ketamineNegative symptomsFrontal cortexRule acquisitionTest changesFirst studySingle repetitionKetamine effectsRepetitionTotal errorDistractibilityReceptor contributionNMDA receptor contributionRecall
1999
Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
Krystal J, D'Souza D, Madonick S, Petrakis I. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients. Schizophrenia Research 1999, 35: s35-s49. PMID: 10190224, DOI: 10.1016/s0920-9964(98)00162-5.Peer-Reviewed Original ResearchConceptsSchizophrenic patientsSubstance abuseTerms of rehospitalizationComorbid substance abuseExacerbation of symptomsHealth care expensesSelf-medication hypothesisBetter prognosisMedical illnessPharmacotherapeutic approachesRational pharmacotherapyNonschizophrenic populationsPatientsVocational functionIllicit substancesCare expensesAbuseVulnerability hypothesisRehospitalizationExacerbationMedicationsPharmacotherapyPrognosisPsychostimulantsIllness
1992
Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?
Krystal J, Price L, Opsahl C, Ricaurte G, Heninger G. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function? The American Journal Of Drug And Alcohol Abuse 1992, 18: 331-341. PMID: 1357957, DOI: 10.3109/00952999209026070.Peer-Reviewed Original ResearchConceptsNeuropsychological functionMDMA useChronic MDMA useWechsler Memory ScaleLeast mild impairmentMemory ScaleNeuropsychological batteryTime of testingMood effectsCognitive functionMemory deficitsMethylenedioxymethamphetamine (MDMA) useDepressed moodMood regulationPreliminary evidenceDeficitsMild impairmentClinical criteriaClinical examinationPreliminary findingsSelective serotoninMoodModerate impairmentAffective disordersPossible detrimental effects